Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

NCT06192004 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06192004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06192004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Terminated
Start date
January 5, 2024
Completion date
April 30, 2025
Enrollment
83 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer